1-2 of 2
Tom Van Meerten, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney, MBBS, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, PhD, Hervé Finel, Irma Khvedelidze, Hannah Hunter, MB,FRCPath,MRCP, Xavier Poire, Bruno Lioure, MD, Karl S Peggs, Robin Foà, MD, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Tom Van Meerten, MD PhD, Juan Jose Bargay, Christoph Schmid, MD, Vergote Vibeke, Arnold Ganser, MD, Luca Castagna, MD, Ghulam J. Mufti, Silvia Montoto, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 701.
https://doi.org/10.1182/blood-2019-123442
Published: 2019
Journal Articles

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Max Topp, MD, Tom Van Meerten, MD PhD, Roch Houot, MD PhD, Monique C. Minnema, Noel Milpied, MD, Pieternella J. Lugtenburg, MD PhD, Catherine Thieblemont, MD PhD, Martin Wermke, MD, Kevin Song, MD, Irit Avivi, MD, John Kuruvilla, MD, Ulrich Dührsen, Prof, MD PhD, Rachel Chu, PhD, Lianqing Zheng, PhD, Vicki Plaks, PhD, Anne Kerber, MD, Marie Jose' Kersten, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 243.
https://doi.org/10.1182/blood-2019-126081
Published: 2019